Relapse protection following early CMV reactivation after HSCT is limited to HLA-C KIR ligand homozygous recipients.

Nikoloudis A, Wagner H, Machherndl-Spandl S, Buxhofer-Ausch V, Strassl I, Stiefel O, Wipplinger D, Milanov R, Kaynak E, Hasengruber P, et al. Relapse protection following early CMV reactivation after HSCT is limited to HLA-C KIR ligand homozygous recipients. Transplant Cell Ther. 2021.